RAD001 in Advanced Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

November 30, 2011

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

RAD001

Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Novartis

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00516165 - RAD001 in Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter